According to data from MarketBeat, EyePoint Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $32.

Source: https://www.etfdailynews.com/2023/12/15/eyepoint-pharmaceuticals-nasdaqeypt-now-covered-by-analysts-at-capital-one-financial/

Cubist Systematic Strategies LLC boosted its stake in EyePoint Pharmaceuticals by 46.6% in the second quarter.

Source: https://www.dailypolitical.com/2023/08/04/eyepoint-pharmaceuticals-eypt-buy-rating-reiterated-at-chardan-capital.html

Legato Capital Management LLC lifted its position in shares of EyePoint Pharmaceuticals by 6.5% in the 2nd quarter.

Source: https://www.dailypolitical.com/2023/08/24/ew-healthcare-partners-l-p-sells-46778-shares-of-eyepoint-pharmaceuticals-inc-nasdaqeypt-stock.html

MetLife Investment Management LLC boosted its stake in EyePoint Pharmaceuticals by 55.5% in the 1st quarter.

Source: https://www.etfdailynews.com/2023/12/15/eyepoint-pharmaceuticals-nasdaqeypt-now-covered-by-analysts-at-capital-one-financial/